In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

The once-weekly investigational twincretin drug is in phase 3 development for obesity and under regulatory review, ... Tirzepatide Excites in Obesity Now Too, Says Lilly - Medscape - Apr 29, 2022.

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with menopause hormone therapy. A Mayo Clinic study revealed that this dual ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

Mounjaro, a tirzepatide injection drug, has been used for treating Type II diabetes. ... Then came a large 72-week study sponsored by Eli Lilly of tirzepatide in 2,539 people with obesity.